The IFRD1 Knouckout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population originating from the HT29 human colorectal adenocarcinoma cell line, providing a loss-of-function model for IFRD1. Generated by gene disruption in a bulk parental culture, these cells retain population heterogeneity, which is advantageous for studies on tumor cell variability, epithelial monolayer responses, and heterogeneous signaling outcomes. The polyclonal format avoids clonal bias and permits the investigation of IFRD1-dependent processes in a context that better reflects the plasticity of intestinal epithelial cells.
The HT29 cell line is a widely used model of colorectal adenocarcinoma, exhibiting an epithelial phenotype and the capacity for enterocytic differentiation under appropriate conditions. These cells are employed to examine epithelial barrier integrity, polarization, mucus production, and response to cytokines or microbial factors. HT29 carries clinically relevant mutations in APC, TP53, and KRAS, providing a genetically defined background for studying how IFRD1 loss influences colorectal tumor biology and therapeutic responses.
IFRD1 functions as a transcriptional co-regulator that integrates signals from inflammatory cytokines and developmental pathways. It is transcriptionally induced by interferon-gamma and tumor necrosis factor-alpha via NF-??B and STAT1, and then interacts with MyoD and histone deacetylase 1 (HDAC1) to modulate gene expression. IFRD1 can repress MyoD transcriptional activity, delaying myogenic differentiation, while promoting p21/CDKN1A expression to control cell cycle progression. In the Notch and BMP axes, IFRD1 interfaces with Notch1, HES1, BMP4, and SMAD1 to regulate lineage commitment, and its role in stress granule assembly highlights involvement in cellular adaptation to proteotoxic or inflammatory insult.
In HT29 colorectal adenocarcinoma cells, IFRD1 knockout is expected to perturb the balance between proliferation and enterocytic differentiation. Loss of IFRD1 may impair differentiation potential by altering the activity of downstream targets such as myogenin and NDRG1, or by modifying HDAC-dependent chromatin remodeling. As IFRD1 operates downstream of tumor necrosis factor-alpha and NF-??B, its ablation is likely to affect inflammatory cytokine responses, potentially impacting barrier function, apoptosis, and immune evasion. These changes could alter the migratory, invasive, and stress-resistant properties of the cells, offering a platform to dissect IFRD1??s role in colorectal cancer plasticity and epithelial homeostasis.
This knockout model supports diverse colorectal cancer and epithelial biology applications. Transcriptomic profiling via RNA-seq, targeted gene expression analysis by RT-qPCR, and protein detection via western blotting for markers such as myogenin and p21 clarify the molecular consequences of IFRD1 loss. Immunofluorescence for epithelial markers (e.g., E-cadherin) assesses barrier integrity, while functional assays in migration, invasion, and apoptosis define phenotypic effects. Drug sensitivity tests and phospho-signaling studies evaluate therapeutic vulnerabilities and stress-kinase pathways, and NF-??B reporter assays directly measure inflammatory signaling modulation. For inquiries or custom configurations, please contact Ascent Research.
